{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T22:40:07Z","timestamp":1746398407454,"version":"3.40.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00059-014-4151-9","type":"journal-article","created":{"date-parts":[[2014,9,29]],"date-time":"2014-09-29T16:09:39Z","timestamp":1412006979000},"page":"790-797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Klinische Pharmakologie der aktuellen antithrombozyt\u00e4ren Substanzen","Clinical pharmacology of current antiplatelet drugs"],"prefix":"10.1007","volume":"39","author":[{"given":"D.","family":"Trenk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"N\u00fchrenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Stratz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Valina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Hochholzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,1]]},"reference":[{"key":"4151_CR1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1056\/NEJM198308183090703","volume":"309","author":"Lewis","year":"1983","unstructured":"Lewis HD Jr, Davis JW, Archibald DG et al (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396\u2013403","journal-title":"N Engl J Med"},{"key":"4151_CR2","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJM198511283132201","volume":"313","author":"Cairns","year":"1985","unstructured":"Cairns JA, Gent M, Singer J et al (1985) Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 313:1369\u20131375","journal-title":"N Engl J Med"},{"key":"4151_CR3","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","volume":"319","author":"Theroux","year":"1988","unstructured":"Theroux P, Ouimet H, McCans J et al (1988) Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 319:1105\u20131111","journal-title":"N Engl J Med"},{"key":"4151_CR4","doi-asserted-by":"crossref","unstructured":"ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2:349\u2013360","DOI":"10.1016\/S0140-6736(88)92833-4"},{"key":"4151_CR5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1148\/radiology.152.3.6463245","volume":"152","author":"Maass","year":"1984","unstructured":"Maass D, Zollikofer CL, Largiader F et al (1984) Radiological follow-up of transluminally inserted vascular endoprostheses: an experimental study using expanding spirals. Radiology 152:659\u2013663","journal-title":"Radiology"},{"key":"4151_CR6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/01.CIR.76.2.450","volume":"76","author":"Schatz","year":"1987","unstructured":"Schatz RA, Palmaz JC, Tio FO et al (1987) Balloon-expandable intracoronary stents in the adult dog. Circulation 76:450\u2013457","journal-title":"Circulation"},{"key":"4151_CR7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/clc.4960060802","volume":"6","author":"Waller","year":"1983","unstructured":"Waller BF (1983) Early and late morphologic changes in human coronary arteries after percutaneous transluminal coronary angioplasty. Clin Cardiol 6:363\u2013372","journal-title":"Clin Cardiol"},{"key":"4151_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-8703(07)80005-6","volume":"126","author":"Haude","year":"1993","unstructured":"Haude M, Erbel R, Issa H et al (1993) Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J 126:15\u201322","journal-title":"Am Heart J"},{"key":"4151_CR9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0735-1097(95)00433-5","volume":"27","author":"Neumann","year":"1996","unstructured":"Neumann FJ, Gawaz M, Ott I et al (1996) Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 27:15\u201321","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR10","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/01.CIR.93.2.229","volume":"93","author":"Gawaz","year":"1996","unstructured":"Gawaz M, Neumann FJ, Ott I et al (1996) Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93:229\u2013237","journal-title":"Circulation"},{"key":"4151_CR11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"Sch\u00f6mig","year":"1996","unstructured":"Sch\u00f6mig A, Neumann FJ, Kastrati A et al (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 334:1084\u20131089","journal-title":"N Engl J Med"},{"key":"4151_CR12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494\u2013502","journal-title":"N Engl J Med"},{"key":"4151_CR13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-2007-996108","volume":"23","author":"Schr\u00f6r","year":"1997","unstructured":"Schr\u00f6r K (1997) Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 23:349\u2013356","journal-title":"Semin Thromb Hemost"},{"key":"4151_CR14","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1161\/CIRCULATIONAHA.105.596627","volume":"113","author":"Frelinger","year":"2006","unstructured":"Frelinger AL III, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113:2888\u20132896","journal-title":"Circulation"},{"key":"4151_CR15","first-page":"51","volume":"6","author":"Nagelschmitz","year":"2014","unstructured":"Nagelschmitz J, Blunck M, Kraetzschmar J et al (2014) Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol 6:51\u201359","journal-title":"Clin Pharmacol"},{"key":"4151_CR16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa003199","volume":"345","author":"Catella-Lawson","year":"2001","unstructured":"Catella-Lawson F, Reilly MP, Kapoor SC et al (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809\u20131817","journal-title":"N Engl J Med"},{"key":"4151_CR17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2007.02800.x","volume":"6","author":"Hohlfeld","year":"2008","unstructured":"Hohlfeld T, Zimmermann N, Weber AA et al (2008) Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 6:166\u2013173","journal-title":"J Thromb Haemost"},{"key":"4151_CR18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1055\/s-0038-1657538","volume":"78","author":"Gachet","year":"1997","unstructured":"Gachet C, Hechler B, Leon C et al (1997) Activation of ADP receptors and platelet function. Thromb Haemost 78:271\u2013275","journal-title":"Thromb Haemost"},{"key":"4151_CR19","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1055\/s-0038-1650674","volume":"76","author":"Mills","year":"1996","unstructured":"Mills DC (1996) ADP receptors on platelets. Thromb Haemost 76:835\u2013856","journal-title":"Thromb Haemost"},{"key":"4151_CR20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"Hollopeter","year":"2001","unstructured":"Hollopeter G, Jantzen HM, Vincent D et al (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202\u2013207","journal-title":"Nature"},{"key":"4151_CR21","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","volume":"48","author":"Hochholzer","year":"2006","unstructured":"Hochholzer W, Trenk D, Bestehorn HP et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742\u20131750","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR22","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919\u2013933","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR23","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.jacc.2007.12.056","volume":"51","author":"Trenk","year":"2008","unstructured":"Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925\u20131934","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR24","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.2217\/14622416.9.9.1251","volume":"9","author":"Geisler","year":"2008","unstructured":"Geisler T, Schaeffeler E, Dippon J et al (2008) CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 9:1251\u20131259","journal-title":"Pharmacogenomics"},{"key":"4151_CR25","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.jacc.2010.02.031","volume":"55","author":"Hochholzer","year":"2010","unstructured":"Hochholzer W, Trenk D, Fromm MF et al (2010) Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. J Am Coll Cardiol 55:2427\u20132434","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR26","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/jama.2011.290","volume":"305","author":"Price","year":"2011","unstructured":"Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention. JAMA 305:1097\u20131105","journal-title":"JAMA"},{"key":"4151_CR27","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","volume":"367","author":"Collet","year":"2012","unstructured":"Collet JP, Cuisset T, Range G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100\u20132109","journal-title":"N Engl J Med"},{"key":"4151_CR28","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1016\/j.jacc.2012.02.026","volume":"59","author":"Trenk","year":"2012","unstructured":"Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol 59:2159\u20132164","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR29","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.ijcard.2012.05.040","volume":"167","author":"Siller-Matula","year":"2013","unstructured":"Siller-Matula JM, Francesconi M, Dechant C et al (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the madonna study. Int J Cardiol 167:2018\u20132023","journal-title":"Int J Cardiol"},{"key":"4151_CR30","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jacc.2013.12.023","volume":"63","author":"Aradi","year":"2014","unstructured":"Aradi D, Tornyos A, Pint\u00e9r T et al (2014) Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63:1061\u20131070","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1124\/dmd.105.007989","volume":"34","author":"Rehmel","year":"2006","unstructured":"Rehmel JL, Eckstein JA, Farid NA et al (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 34:600\u2013607","journal-title":"Drug Metab Dispos"},{"key":"4151_CR32","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1527-3466.2007.00027.x","volume":"25","author":"Jakubowski","year":"2007","unstructured":"Jakubowski JA, Winters KJ, Naganuma H et al (2007) Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 25:357\u2013374","journal-title":"Cardiovasc Drug Rev"},{"key":"4151_CR33","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1538-7836.2007.02598.x","volume":"5","author":"Sugidachi","year":"2007","unstructured":"Sugidachi A, Ogawa T, Kurihara A et al (2007) The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel\u2019s active metabolite. J Thromb Haemost 5:1545\u20131551","journal-title":"J Thromb Haemost"},{"key":"4151_CR34","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001\u20132015","journal-title":"N Engl J Med"},{"key":"4151_CR35","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","volume":"7","author":"VAN","year":"2009","unstructured":"VAN Giezen JJ, Nilsson L, Berntsson P et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7:1556\u20131565","journal-title":"J Thromb Haemost"},{"key":"4151_CR36","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jacc.2013.11.032","volume":"63","author":"Angiolillo","year":"2014","unstructured":"Angiolillo DJ, Curzen N, Gurbel P et al (2014) Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: results of the SWAP-2 study (Switching Anti Platelet-2). J Am Coll Cardiol 63:1500\u20131509","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","volume":"51","author":"Teng","year":"2012","unstructured":"Teng R (2012) Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor. Clin Pharmacokinet 51:305\u2013318","journal-title":"Clin Pharmacokinet"},{"key":"4151_CR38","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/j.1538-7836.2011.04419.x","volume":"9","author":"Storey","year":"2011","unstructured":"Storey RF, Bliden KP, Ecob R et al (2011) Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost 9:1730\u20131737","journal-title":"J Thromb Haemost"},{"key":"4151_CR39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045\u20131057","journal-title":"N Engl J Med"},{"key":"4151_CR40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/CIRCINTERVENTIONS.112.972323","volume":"5","author":"Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Xanthopoulou I, Gkizas V et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5:797\u2013804","journal-title":"Circ Cardiovasc Interv"},{"key":"4151_CR41","first-page":"P1437","volume":"102","author":"Trenk","year":"2013","unstructured":"Trenk D, Ferenc M, Schmitz R et al (2013) Delayed onset of antiplatelet effect of prasugrel and ticagrelor in patients with acute coronary syndromes. Clin Res Cardiol 102(Suppl 1):P1437","journal-title":"Clin Res Cardiol"},{"key":"4151_CR42","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61:1601\u20131606","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","volume":"34","author":"Angiolillo","year":"2012","unstructured":"Angiolillo D, Schneider D, Bhatt D et al (2012) Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (champion) trials. J Thromb Thrombolysis 34:44\u201355","journal-title":"J Thromb Thrombolysis"},{"key":"4151_CR44","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","volume":"368","author":"Bhatt","year":"2013","unstructured":"Bhatt DL, Stone GW, Mahaffey KW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368:1303\u20131313","journal-title":"N Engl J Med"},{"key":"4151_CR45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","volume":"307","author":"Angiolillo","year":"2012","unstructured":"Angiolillo DJ, Firstenberg MS, Price MJ et al (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. JAMA 307:265\u2013274","journal-title":"JAMA"},{"key":"4151_CR46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","volume":"121","author":"Steinhubl","year":"2008","unstructured":"Steinhubl SR, Oh JJ, Oestreich JH et al (2008) Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb Res 121:527\u2013534","journal-title":"Thromb Res"},{"key":"4151_CR47","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1538-7836.2008.03020.x","volume":"6","author":"Dovlatova","year":"2008","unstructured":"Dovlatova NL, Jakubowski JA, Sugidachi A et al (2008) The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 6:1153\u20131159","journal-title":"J Thromb Haemost"},{"key":"4151_CR48","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.thromres.2012.07.021","volume":"130","author":"Ravnefjord","year":"2012","unstructured":"Ravnefjord A, Weilitz J, Emanuelsson BM et al (2012) Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model. Thromb Res 130:622\u2013628","journal-title":"Thromb Res"},{"key":"4151_CR49","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0735-1097(01)01165-2","volume":"37","author":"Neumann","year":"2001","unstructured":"Neumann FJ, Hochholzer W, Pogatsa-Murray G et al (2001) Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 37:1323\u20131328","journal-title":"J Am Coll Cardiol"},{"key":"4151_CR50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(11)61872-2","volume":"379","author":"Thiele","year":"2012","unstructured":"Thiele H, W\u00f6hrle J, Hambrecht R et al (2012) Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial. Lancet 379:923\u2013931","journal-title":"Lancet"},{"key":"4151_CR51","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0090-9556(24)14939-2","volume":"27","author":"Vickers","year":"1999","unstructured":"Vickers S, Theoharides AD, Arison B et al (1999) In vitro and in vivo studies on the metabolism of tirofiban. Drug Metab Dispos 27:1360\u20131366","journal-title":"Drug Metab Dispos"},{"key":"4151_CR52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1008904310194","volume":"11","author":"Smith","year":"2001","unstructured":"Smith BS, Gandhi PJ (2001) Pharmacokinetics and pharmacodynamics of low-molecular-weight heparins and glycoprotein IIb\/IIIa receptor antagonists in renal failure. J Thromb Thrombolysis 11:39\u201348","journal-title":"J Thromb Thrombolysis"},{"key":"4151_CR53","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"Task","year":"2012","unstructured":"Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569\u20132619","journal-title":"Eur Heart J"},{"key":"4151_CR54","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","unstructured":"Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999\u20133054","journal-title":"Eur Heart J"},{"key":"4151_CR55","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","unstructured":"Valgimigli M, Tebaldi M, Campo G et al (2012) Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the fabolus pro (facilitation through aggrastat by dropping or shortening infusion line in patients with st-segment elevation myocardial infarction compared to or on top of prasugrel given at loading dose) trial. JACC Cardiovasc Interv 5:268\u2013277","journal-title":"JACC Cardiovasc Interv"},{"key":"4151_CR56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/bja\/aep373","volume":"104","author":"Savonitto","year":"2010","unstructured":"Savonitto S, D\u2019urbano M, Caracciolo M et al (2010) Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of \u201abridging\u2018 antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 104:285\u2013291","journal-title":"Br J Anaesth"},{"key":"4151_CR57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","volume":"90","author":"Merlini","year":"1994","unstructured":"Merlini PA, Bauer KA, Oltrona L et al (1994) Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 90:61\u201368","journal-title":"Circulation"},{"key":"4151_CR58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD et al (2012) Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366:9\u201319","journal-title":"N Engl J Med"},{"key":"4151_CR59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S et al (2011) Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365:699\u2013708","journal-title":"N Engl J Med"},{"key":"4151_CR60","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","volume":"366","author":"Tricoci","year":"2012","unstructured":"Tricoci P, Huang Z, Held C et al (2012) Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 366:20\u201333","journal-title":"N Engl J Med"},{"key":"4151_CR61","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","volume":"366","author":"Morrow","year":"2012","unstructured":"Morrow DA, Braunwald E, Bonaca MP et al (2012) Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 366:1404\u20131413","journal-title":"N Engl J Med"},{"key":"4151_CR62","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","volume":"12","author":"Storey","year":"2006","unstructured":"Storey RF (2006) Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 12:1255\u20131259","journal-title":"Curr Pharm Des"},{"key":"4151_CR63","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1161\/01.CIR.0000160869.75810.98","volume":"111","author":"Hochholzer","year":"2005","unstructured":"Hochholzer W, Trenk D, Frundi D et al (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111:2560\u20132564","journal-title":"Circulation"},{"key":"4151_CR64","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jcin.2013.06.011","volume":"6","author":"Siller-Matula","year":"2013","unstructured":"Siller-Matula JM, Trenk D, Schr\u00f6r K et al (2013) Response variability to P2Y12 receptor inhibitors: expectations and reality. JACC Cardiovasc Interv 6:1111\u20131128","journal-title":"JACC Cardiovasc Interv"},{"key":"4151_CR65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1472-8206.2011.00986.x","volume":"26","author":"Schr\u00f6r","year":"2011","unstructured":"Schr\u00f6r K, Siller-Matula JM, Huber K (2011) Pharmacokinetic basis of the antiplatelet action of prasugrel. Fundam Clin Pharmacol 26:39\u201346","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-014-4151-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-014-4151-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-014-4151-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T22:13:10Z","timestamp":1746396790000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-014-4151-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":65,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1007\/s00059-014-4151-9","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2014,10,1]]}}}